A comprehensive panel discussion by cardiometabolic risk management experts addresses the impact, prevention, management, and treatment of cardiometabolic conditions, exploring adherence challenges, care coordination strategies, recent studies, and innovative approaches to improve patient outcomes.
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.